---
title: "000078.SZ (000078.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000078.SZ/news.md"
symbol: "000078.SZ"
name: "000078.SZ"
parent: "https://longbridge.com/en/quote/000078.SZ.md"
datetime: "2026-05-21T05:41:41.746Z"
locales:
  - [en](https://longbridge.com/en/quote/000078.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000078.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000078.SZ/news.md)
---

# 000078.SZ (000078.SZ) — Related News

### [NEPTUNUS: Stock trading has serious abnormal fluctuations, and there is a possibility of delisting risk warning](https://longbridge.com/en/news/287046115.md)
*2026-05-20T10:17:18.000Z*
> ST NEPTUNUS announced that due to the cumulative deviation value of the daily closing price drop exceeding 12% over thre

### [ST NEPTUNUS had a net outflow of 446,900 yuan, and lawyers stated that affected shareholders may be able to claim compensation due to the previous internal control being rejected](https://longbridge.com/en/news/286386525.md)
*2026-05-14T06:24:15.000Z*
> On May 13th, ST NEPTUNUS had a transaction volume of 6.1619 million yuan, with a net outflow of 446,900 yuan from major 

### [NEPTUNUS had a net outflow of 1.2138 million yuan, and a lawyer stated that shareholders who were harmed due to the previous internal control rejection may be able to claim compensation](https://longbridge.com/en/news/285963733.md)
*2026-05-11T14:49:11.000Z*
> On May 11, ST Neptunus had a transaction volume of 7.1844 million yuan, with a net outflow of 1.2138 million yuan from m

### [Nearly 1.3 billion yuan of illegal fund operations exposed, the established pharmaceutical company NEPTUNUS is "capped"](https://longbridge.com/en/news/285649424.md)
*2026-05-08T01:49:08.000Z*
> Shenzhen Neptunus Bioengineering Co., Ltd. has been subjected to other risk warnings due to internal control deficiencie

### [Internal control issued a negative opinion, NEPTUNUS faces delisting risk warning](https://longbridge.com/en/news/284858553.md)
*2026-05-01T01:50:13.000Z*
> NEPTUNUS received a negative opinion due to internal control deficiencies and is facing a delisting risk warning. In 202

### [【Caitong AH】NEPTUNUS lost over 500 million yuan last year, with losses exceeding 4 billion yuan for four consecutive years](https://longbridge.com/en/news/284725510.md)
*2026-04-30T08:33:18.000Z*
> In 2025, NEPTUNUS released its annual report, with operating revenue of 26.668 billion yuan, a year-on-year decrease of 

### [NEPTUNUS may be subject to delisting risk warning](https://longbridge.com/en/news/284661512.md)
*2026-04-29T23:59:04.000Z*
> NEPTUNUS announced that it may face delisting risk warning due to the negative audit report issued by Grant Thornton on 

### ["A-Share Focus" The mainland will improve the drug price formation mechanism, and the innovative drug concept is gaining strength](https://longbridge.com/en/news/282771293.md)
*2026-04-15T02:19:00.000Z*
> Mainland China will improve the drug pricing mechanism, and the concept of innovative drugs is gaining strength. HISUN a

### ["A-Share Focus" Innovative drug concept is active, NEPTUNUS and other stocks hit the daily limit, WuXi AppTec AH both rose over 3%](https://longbridge.com/en/news/282119719.md)
*2026-04-09T01:49:00.000Z*
> The innovative drug concept was active in the morning session, with NEPTUNUS, JINLING PHARM., and YIBAI PHARMACEUTICAL h

### [](https://longbridge.com/en/news/282117955.md)
*2026-04-09T01:38:25.000Z*
> The A-share generic drug concept rose in early trading, with HPGC up over 8%, and Luoxin Pharmaceutical, NEPTUNUS, FENGY